Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Kentucky Cancer Clinic
mi
from
Hazard, KY
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Kentucky Cancer Clinic
mi
from
Hazard, KY
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Annapolis Oncology Center
mi
from
Annapolis, MD
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Annapolis Oncology Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
North Canton Medical Clinic Center
mi
from
Canton, OH
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
North Canton Medical Clinic Center
mi
from
Canton, OH
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Guthrie Clinic, Ltd.
mi
from
Sayre, PA
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Guthrie Clinic, Ltd.
mi
from
Sayre, PA
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Rhode Island Hospital
mi
from
Providence, RI
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Blue Ridge Cancer Care
mi
from
Christiansburg, VA
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Blue Ridge Cancer Care
mi
from
Christiansburg, VA
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Providence Western Washington Oncology
mi
from
Lacey, WA
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Providence Western Washington Oncology
mi
from
Lacey, WA
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Acrc/Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Acrc/Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Palm Beach Cancer Institute, LLC
mi
from
West Palm Beach, FL
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Palm Beach Cancer Institute, LLC
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Clintell, Inc.
mi
from
Skokie, IL
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Clintell, Inc.
mi
from
Skokie, IL
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
North Mississippi Hematology And Oncology Associates, Ltd
mi
from
Tupelo, MS
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
North Mississippi Hematology And Oncology Associates, Ltd
mi
from
Tupelo, MS
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Kaiser Permanente Oncology/Hematology
mi
from
Portland, OR
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Kaiser Permanente Oncology/Hematology
mi
from
Portland, OR
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Cancer Center At Cookeville Regional Medical Center
mi
from
Cookeville, TN
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Cancer Center At Cookeville Regional Medical Center
mi
from
Cookeville, TN
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
University of Tennessee Cancer Institute
mi
from
Memphis, TN
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
University of Tennessee Cancer Institute
mi
from
Memphis, TN
Click here to add this to my saved trials
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Fortaleza,
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Fortaleza,
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Yale University School of Medicine
mi
from
New Haven, CT
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Hematology Oncology P.C.
mi
from
Stamford, CT
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Hematology Oncology P.C.
mi
from
Stamford, CT
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Mass General Hospital
mi
from
Boston, MA
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Mass General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Henry Ford Hospital
mi
from
Detroit, MI
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Oregon Health and Science University
mi
from
Portland, OR
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Hema/Oncology Assoc. Of Nepa
mi
from
Dunmore, PA
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Hema/Oncology Assoc. Of Nepa
mi
from
Dunmore, PA
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Cancer Center of the Carolinas
mi
from
Greenville, SC
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Cancer Center of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Bahia Blanca,
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Bahia Blanca,
Click here to add this to my saved trials
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
Status: Enrolling
Updated:  9/25/2015
Stanford University School of Medicine
mi
from
Stanford, CA
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
Status: Enrolling
Updated: 9/25/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer
Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer
Status: Enrolling
Updated:  9/26/2015
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer
Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer
Status: Enrolling
Updated: 9/26/2015
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
African American Families and Lung Cancer Study
African American Families and Lung Cancer Study
Status: Enrolling
Updated:  9/26/2015
MedStar Washington Hospital Center
mi
from
Washington,
African American Families and Lung Cancer Study
African American Families and Lung Cancer Study
Status: Enrolling
Updated: 9/26/2015
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, MD: A Pilot Study of Biomarkers
Status: Enrolling
Updated:  9/26/2015
Johns Hopkins University
mi
from
Baltimore, MD
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, MD: A Pilot Study of Biomarkers
Status: Enrolling
Updated: 9/26/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated:  9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated: 9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  9/28/2015
M D Anderson Cancer Center
mi
from
Houston, TX
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 9/28/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors
Status: Enrolling
Updated:  9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors
Status: Enrolling
Updated: 9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
Status: Enrolling
Updated:  9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
Status: Enrolling
Updated: 9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
Psychosocial Adjustment During the Post-Radiation Treatment Transition
Status: Enrolling
Updated:  9/29/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
Psychosocial Adjustment During the Post-Radiation Treatment Transition
Status: Enrolling
Updated: 9/29/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/29/2015
New York University
mi
from
New York, NY
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/29/2015
New York University
mi
from
New York, NY
Click here to add this to my saved trials
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated:  9/30/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated: 9/30/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Surveillance For New Lung Primaries
Low Dose Helical Computed Tomographic (CT) Screening Followed by Anatomic Co-Registered Computed Tomography With Positron Emission Tomography (CT/PET) for Patients With Indeterminate (5-9 mm) Nodules
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Surveillance For New Lung Primaries
Low Dose Helical Computed Tomographic (CT) Screening Followed by Anatomic Co-Registered Computed Tomography With Positron Emission Tomography (CT/PET) for Patients With Indeterminate (5-9 mm) Nodules
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials